<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326973</url>
  </required_header>
  <id_info>
    <org_study_id>17-518</org_study_id>
    <nct_id>NCT03326973</nct_id>
  </id_info>
  <brief_title>Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors</brief_title>
  <official_title>Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify and describe long-term quality of life (QOL) issues in patients with metastatic&#xD;
      melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12&#xD;
      months and remain on maintenance checkpoint inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>total score of Global QOL overall health index</measure>
    <time_frame>1 year</time_frame>
    <description>On the EQ-5D-3L, respondents are asked to indicate their health state by marking the box associated with the most appropriate statement in each of the 5 dimensions, resulting in a one digit number expressing the level (1-3) selected for that dimension from no problems to extreme problems.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">107</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>online or telephone survey</arm_group_label>
    <description>This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EuroQoL EQ-5D-3L</intervention_name>
    <description>Overall QOL</description>
    <arm_group_label>online or telephone survey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EORTC QLQ-C30</intervention_name>
    <description>General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales</description>
    <arm_group_label>online or telephone survey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRO-CTCAE</intervention_name>
    <description>Additional potential immune-specific symptoms</description>
    <arm_group_label>online or telephone survey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fatigue severity score questionnaire</intervention_name>
    <description>Fatigue severity</description>
    <arm_group_label>online or telephone survey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>The COST</intervention_name>
    <description>Financial toxicity; satisfaction with ability to work</description>
    <arm_group_label>online or telephone survey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physician information</intervention_name>
    <description>Details on outside health providers</description>
    <arm_group_label>online or telephone survey</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The melanoma service has agreed to provide this research team with access to a list of&#xD;
        patients who are potentially eligible for this survey.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be able to speak and read English&#xD;
&#xD;
          -  Be able to provide informed consent&#xD;
&#xD;
          -  Have been diagnosed with metastatic melanoma at age 18 years or older&#xD;
&#xD;
          -  Have been treated with either single agent or combination checkpoint inhibitor&#xD;
&#xD;
          -  Be at least 12 months since first dose of above named agents&#xD;
&#xD;
          -  Received no other systemic therapy after initiation of immunotherapy (interval&#xD;
             radiation or surgery will be permitted based on review with primary treating medical&#xD;
             oncologist)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cognitive, visual, or motor impairment such that they cannot complete&#xD;
             the survey as assessed by the research or clinical team&#xD;
&#xD;
          -  Patients who developed a subsequent cancer after starting on checkpoint inhibitor(s),&#xD;
             exclusive of non-melanoma superficial skin cancers&#xD;
&#xD;
          -  Patients with clinical documentation of progressive disease on the most recent&#xD;
             assessment in the electronic medical record&#xD;
&#xD;
          -  Patients with symptomatic progression but continue on immunotherapy&#xD;
&#xD;
               -  Note: For any patients where the disease status is not clear, we will confirm&#xD;
                  that the disease is either stable or responsive with their primary treating&#xD;
                  medical oncologist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Korenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life (QoL)</keyword>
  <keyword>17-518</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

